Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Sareum Holdings PLC (SAR.L) US Patent Notice of Allowance for SDC-1802
Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
Sareum Holdings PLC (SAR.L) Covid-19 Research Project Results
Completed Covid-19 Research Project Delivers Encouraging Results
Redx Pharma plc (LON:REDX) Sale of pan-RAF inhibitor programme
Redx to receive $3.5 million upfront, up to $203 million in milestone payments and royalty payments
Sareum Holdings Plc (AIM:SAR) Sierra Oncology Granted US and EU Patents
Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made by Sierra Oncology, Inc. yesterday stating that selection patents* that explicitly protect the Chk1